Roivant Sciences Ltd. (ROIV) Stock Price Quote, News &…

Summary

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Website

roivant.com

Location

London, D0, GB

Phone44 2074 003 347

Employees721

CEOMatthew Gline

Sector

Health Care

Industry

Pharmaceuticals

IPO DateDec 8, 2020

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

In April 2018, the Company entered into an agreement with Roivant Sciences Ltd. (“Roivant”), its largest shareholder, to launch Genevant Sciences Ltd., a company focused on nucleic acid- and gene editing-based therapeutics enabled by the Company’s LNP and ligand conjugate delivery technologies. The Company licensed rights to its LNP and ligand conjugate delivery platforms to Genevant outside of hepatitis B (“HBV”), except to the extent certain ri …
Arbutus Biopharma CorpRoivant Sciences Ltd.·10-Q - Quarterly report Q3·Q3 26·10 Nov
… o engages in private investment activities. From April 2016 through June 2025, Dr. Kluft served as Vice President, Special Projects and, prior to that, Vice President, Investments (previously Business Development) at Roivant Sciences, where he was closely involved in the sourcing, evaluation and execution of transactions that resulted in the formation of several Roivant subsidiary companies, including Immunovant, Urovant, and Pulmovant, among oth …
Talawar Tx Inc.Roivant Sciences Ltd.·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·9 Nov
… in July 2021 until JATT Acquisition Corp completed its business combination with Zura Bio in March 2023. Prior to that, Dr. Sidhu co-founded Izana Bioscience and served as its CEO from November 2017 until its sale to Roivant Sciences in July 2020. Dr. Sidhu also co-founded Pathios Therapeutics in 2017 and served as co-founder and CEO of Akaza Bioscience from 2019 to 2021. Dr. Sidhu gained medical experience during his time in Cardiology and Gener …
JATT II Acquisition Corp.Roivant Sciences Ltd.·DEFM14A - Definitive proxy statement (merger)·Q4 26·9 Nov
… mmunovant Sciences Ltd., or ISL, and HSAC consummated the transactions contemplated under that certain Share Exchange Agreement dated as of September 29, 2019 by and among HSAC, ISL and the stockholders of ISL and Roivant Sciences Ltd., following the approval at the special meeting of the stockholders of HSAC held on December 16, 2019, which we refer to as the Business Combination. In connection with the closing of the Business Combination, we ch …
Immunovant, Inc.Roivant Sciences Ltd.·S-3ASR - Automatic shelf registration statement (S-3)·Q3 27·9 Nov
In August 2018, the Company entered into amended and restated services agreements (each a “Services Agreement” and together the “Services Agreements”) with Roivant Sciences, Inc. (“RSI”) and RSG, under which RSI and RSG agreed to provide services related to development, administrative and financial activities to the Company. RSI assigned its Services Agreement to RSL effective April 1, 2025. Under each Services Agreement, the Company will pay or …
Immunovant, Inc.Roivant Sciences Ltd.·10-Q - Quarterly report Q2·Q2 27·9 Nov
… -founder of Tourmaline Bio, where he served as Chief Executive Officer from September 2021 through its acquisition by Novartis, which closed in October 2025. Earlier in his career, Dr. Kulkarni held multiple roles at Roivant Sciences from July 2018 to June 2020, including Chief Operating Officer of Immunovant, Inc., Vice President of Special Projects and Ombudsman to the Investment Committee. Prior to Roivant Sciences, Dr. Kulkarni was an Investm …
Research Alliance Corp IIIRoivant Sciences Ltd.·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·4 Nov

Key Stats

Trading

Px/Chg 1D$35.72 / +0.62%

Avg Volume5.87M

Beta0.71

Mkt Cap25.80B

FD Mkt Cap25.03B

Float

Shrs Out/Float722.41M / 577.47M

Short Float0.06%

Days to Cover4.27

Stock Repurchased$319.50M

Current Valuation

EV25.25B

EV/EBITDA-59.55

EV/Sales3,057.35

P/B5.70

P/S3,124.01

FCF Yield-0.64%

ROE-6.62%

ROA-5.23%

Current Ratio18.37

Estimates

P/E-86.08

Est P/E0.00

Est EPS-0.29

Est PEG0.00

Valuation

Metric	5Yr Avg	Feb '23	Aug '23	Aug '24	Aug '25	Oct '26
PRICE-BASED RATIOS
Price / Earnings	4.83	-6.32	-8.17	1.95	-48.46	85.16
Price / Sales	2,228.92	96.55	261.56	259.78	286.88	10,239.82
Price / Book Value	3.85	3.22	7.12	1.42	1.78	5.70
Price / Free Cash Flow	-38.92	-7.68	-9.63	-11.08	-9.87	-156.32
ENTERPRISE VALUE METRICS
Enterprise Value	9,176.5	3,965.9	7,501.4	2,942.2	6,219.2	25,253.7
Enterprise Value / Sales	2,126.99	71.73	237.91	89.94	214.06	10,021.32
Enterprise Value / EBITDA	6.47	-4.35	-9.49	-3.66	-5.66	55.54
Enterprise Value / EBIT	6.57	-4.33	-9.27	-3.57	-5.58	55.61

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Mar '22	Mar '23	Mar '24	Mar '25	Mar '26
INCOME STATEMENT
Revenue	-37.8%	55.3	31.5	32.7	29.1	8.3
Gross Income	-37.7%	46.3	28.5	31.1	28.1	7.0
EBITDA	-26.8%	-910.8	-790.2	-802.9	-1,099.6	-261.2
EBIT	-26.7%	-916.7	-809.0	-824.9	-1,113.7	-264.6
Net Income	-22.8%	-845.3	-1,009.0	4,348.9	-172.0	-299.8
EPS (Diluted)	-23.6%	-1.26	-1.42	5.23	-0.24	-0.43
BALANCE SHEET
Cash & ST Inv	20.2%	2,060.4	1,681.8	6,541.1	4,886.9	4,295.7
Total Assets	22%	2,585.1	2,389.6	7,222.5	5,436.9	5,728.0
Total Liabilities	-4.5%	523.7	782.0	774.0	249.7	435.6
Total Shareholder Equity	28.6%	1,656.9	1,157.8	5,968.6	4,687.6	4,527.4
CASH FLOW
Net Operating Cash Flow	2.6%	-677.7	-843.4	-765.3	-839.5	-750.3
Cap Ex	-17.2%	-17.4	-12.7	-1.4	-4.6	-8.2
Free Cash Flow	2.2%	-695.2	-856.1	-766.7	-844.1	-758.6

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		39.62
Basic Shares		722.41
Market Cap		28,621.7
Diluted Shares		693.86
Fully Diluted Shares Outstanding		693.86
Fully Diluted Market Cap		27,490.9
+Consolidated Debt		107.4
−In-the-Money Convertible Debt		—
+Capital Leases		96.3
+Operating Leases		—
−Cash & Equivalents		-1,423.1
−Short-term Investments		-2,872.6
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		765.0
+Pension Liabilities		—
Enterprise Value		28,071.1

Segment data

Revenue

by Products and services

Reportable Segment100%

Related companies